Acute migraine medication use
migraine, days/month, ICHD-3
MIGRAINE, ACUTE MIGRAINE
At baseline, patients across treatment groups were using acute migraine medications for ~ 11 days/month, generally above the ICHD-3 threshold for acute medication overuse, depending on type of acute medication used. In all groups, patients used ~ 5 fewer acute migraine medication days/month during the first eptinezumab dosing interval compared to baseline (Weeks 1–12 for patients initially treated with eptinezumab and Weeks 25–36 for patients switched from placebo to eptinezumab). Thus, the population mean for acute medication use was reduced to below ICHD-3 thresholds for acute medication overuse. Use remained at similarly reduced levels for the remainder of eptinezumab treatment (Fig. Mean changes from baseline in acute migraine medication days/month (MMRM; efficacy analysis set). Acute migraine medication types included ergotamine, triptan, simple analgesic, combination analgesic, and opioid. BL, baseline; Epti, eptinezumab; LS, least squares; MMRM, mixed model for repeated measures